

REMARKS

The first paragraph of the specification has been amended to include reference to certain additional parent applications and to include numbering to further clarify the relationship of certain parent applications. The amendments do not add any new issues or new matter and thus entry is respectfully requested. There are no amendments to the claims. Claims 22 to 25, 37, and 39 to 138 are under consideration.

The Examiner approved the proposed drawing corrections, and required corrected drawings. Action at page 2. As indicated above, applicants request amendment of the application to include replacement drawing sheets for Figures 4, 13, and 15, with the corrections.

The Examiner indicated that the oath or declaration is defective. Action at page 2. Inventorship of this application is being changed in view of prior amendments of the claims. Along with this Amendment, a Request To Correct Inventorship is being submitted. The Request To Correct Inventorship includes copies of six separate Declaration and Power of Attorney ("Declaration") documents, each signed by one of the six correct inventors after the inventorship has been changed.

The undersigned notes that there is an error in the list of application numbers listed on the first page of each copy of the Declaration. Specifically, in the fifth entry, Application No. 07/506,**222** should have been Application No. 07/506,**522**. The error is minimal, because the filing date and U.S. Patent No. 5,075,222 are listed correctly in that entry. Moreover, the error is harmless, because the correct application number is included in the first paragraph of the specification, and there is no requirement that a declaration list applications for which 35 U.S.C. § 120 benefit is claimed.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

The Examiner rejected claims 22 to 25, 37, and 39 to 138 under the judicially created doctrine of obviousness-type double patenting in view of U.S. Patent No. 5,075,222. See Action at page 3. Solely to expedite prosecution, applicants submit two separate terminal disclaimers, one for each of the two joint assignees of this application and U.S. Patent No. 5,075,222. The two joint assignees are Amgen Inc. and The Regents of the University of Colorado. Accordingly, this rejection is moot.

Applicants submit that the application is in condition for allowance. Thus, applicants respectfully request issuance of a Notice of Allowance.


Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: February 5, 2004

By:



M. Paul Barker
Reg. No. 32,013

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com